PCRX Q1 2024 Earnings — Pacira BioSciences, Inc. Revenue & Financial Results | Market Cap Arena

PCRXPacira BioSciences, Inc.

$971M

Q1 2024 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$167M+4.2% YoY

Gross Profit

$120M71.6% margin

Operating Income

$13M7.9% margin

Net Income

$9M5.4% margin

EPS (Diluted)

$0.19

QoQ Revenue Growth

-7.8%

Cash Flow

Operating Cash Flow

$49M

Free Cash Flow

$46M

Stock-Based Comp.

$13M

Balance Sheet

Total Assets

$1.6B

Total Liabilities

$691M

Stockholders' Equity

$892M

Cash & Equivalents

$184M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$167M	$160M	+4.2%
Gross Profit	$120M	$111M	+7.5%
Operating Income	$13M	-$3M	+527.4%
Net Income	$9M	-$20M	+146.0%

Revenue Segments

Product

$166M51%

EXPAREL

$132M41%

ZILRETTA

$26M8%

Bupivacaine Liposome Injectable Suspension

$3M1%